[1. Testa B, Mayer JB. Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry and Enzymology, Wiley-VCH, 2003.10.1002/9783906390444]Search in Google Scholar
[2. Ettmayer P, Amidon GL, Clement B et al. Lessons learned from marketed and investigational prodrugs. J Med Chem. 2004;47(10):2393-2240.10.1021/jm030381215115379]Search in Google Scholar
[3. Testa B. Prodrug research: futile or fertile. Biochem Pharmacol. 2004;68(11):2097-2106.10.1016/j.bcp.2004.07.00515498500]Search in Google Scholar
[4. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7:255-270.10.1038/nrd246818219308]Search in Google Scholar
[5. Rautio J, Laine K, Gynther M, et al. Prodrug approaches for CNS delivery. AAPS J. 2008;10:92-102.10.1208/s12248-008-9009-8275145418446509]Search in Google Scholar
[6. Jilani JA, Idkaidek NM, Alzoubi KH. Synthesis, In Vitro and In Vivo Evaluation of the N-ethoxycarbonylmorpholine Ester of Diclofenac as a Prodrug. Pharmaceuticals (Basel). 2014;7(4):453-63.10.3390/ph7040453401470224736104]Search in Google Scholar
[7. Wohl AR, Michel AR, Kalscheuer S, et al. Silicat esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, andprodrug potential. J Med Chem. 2014;57(6):2368-2379.10.1021/jm401708f398335124564494]Search in Google Scholar
[8. Liu KS, Hsieh PW, Aljuffali IA, et al. Impact of ester promoieties on transdermal delivery of ketorolac. J Pharm Sci. 2014;103(3):974-986.10.1002/jps.2388824481782]Search in Google Scholar
[9. Diez-Torrubia A, Cabrera S, de Castro S, et al. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. Eur J Med Chem. 2013;70:456-468.10.1016/j.ejmech.2013.10.00124185376]Search in Google Scholar
[10. Lai L, Xu Z, Zhou J, et al. Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem. 2008;283(14):9318-9327.10.1074/jbc.M709530200243103218256025]Search in Google Scholar
[11. Rautio J, Mannhold R, Kubinyi H, Folkers G. Prodrugs and Targeted Delivery: Towards Better ADME Properties, Volume 47, Wiley-VCH Verlag Gmbh & Co KGA, Weinheim, 2011.10.1002/9783527633166]Search in Google Scholar
[12. Chiodo F, Marradi M, Calvo J, et al. Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein J Org Chem. 2014;10:1339-1346.10.3762/bjoc.10.136407745524991287]Search in Google Scholar
[13. Vivekkumar K Redasani, Sanjay B. Bari. Prodrug Design: Perspectives, Approaches and Applications. Elsevier London, 2015.10.1016/B978-0-12-803519-1.00011-8]Search in Google Scholar
[14. Albert A. Chemical aspects of selective toxicity. Nature. 1958;182:421-422.10.1038/182421a013577867]Search in Google Scholar
[15. Wermuth CG, Ganellin CR, Lindberg P, et al. “Glossaryis of terms used in medicinal chemistry (IUPAC Recommendations 1998)”. Pure and Applied Chemistry. 1998;70(5):1129.10.1351/pac199870051129]Search in Google Scholar
[16. N’Da DD. Prodrug strategies for enhancing the percutaneous absorption of drugs. Molecules. 2014;19(12):20780-20807.10.3390/molecules191220780627186725514222]Search in Google Scholar
[17. Forde E, Devocelle M. Pro-moieties of antimicrobial peptide prodrugs. Molecules. 2015;20(1):1210-1227.10.3390/molecules20011210627266825591121]Search in Google Scholar
[18. Wermuth CG, Aldous D, Raboisson P, et al. The practice of Medicinal Chemistry, fourth edition, Academic Press, London, 2015;657-692.]Search in Google Scholar
[19. Vert M, Doi Y, Hellwich K, et al. Terminology for biorelated polymers and applications (IUPAC Recommendations 2012)”. Pure and Applied Chemistry 2012;84(2):377-410.10.1351/PAC-REC-10-12-04]Search in Google Scholar
[20. Das N, Dhanawat M, Dash M. Codrug: An efficient approach for drug optimization. Eur J of Pharm Sci. 2010;41:571-588.10.1016/j.ejps.2010.09.01420888411]Search in Google Scholar
[21. Leppänen J, Huuskonen J, Nevalainen T, et al. Design and synthesis of a novel L-dopa-entacapone codrug. Med Chem. 2002;45(6):1379-1382.10.1021/jm010980d11882007]Search in Google Scholar
[22. Bodor N, Buchwald P. Soft drug design: General principles and recent applications. Medicinal Research Reviews. 2000;20(1):58-101.10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X]Search in Google Scholar
[23. Takácsné Novák K. A prodrug stratégia a gyógyszerkutatásban: bevált módszerek és új irányok. Gyógyszerészet. 2013;57:451-459.]Search in Google Scholar
[24. Keserű GyM. A gyógyszerkutatás kémiája. Akadémiai Kiadó, Budapest, 2011;539-564.]Search in Google Scholar
[25. Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. Pharmacol Rep. 2013;65(1):1-14.10.1016/S1734-1140(13)70959-9]Search in Google Scholar
[26. Stella VJ. Prodrugs: some thoughts and current issues. J Pharm Sci. 2010;99:4755-4765.10.1002/jps.22205]Search in Google Scholar
[27. Stella VJ, Burchardt RT, Hageman MJ, et al. Prodrugs: Challenges and Rewards. Part 1. Springer, New York, 2007.10.1007/978-0-387-49785-3]Search in Google Scholar
[28. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev. 2007;59(7):677-694.10.1016/j.addr.2007.05.013]Search in Google Scholar
[29. Kokil GR, Rewatkar PV. Bioprecursor prodrugs: molecular modification of the active principle. Mini Rev Med Chem. 2010;10:1316-1330.10.2174/138955710793564179]Search in Google Scholar
[30. Wu KM. A new classification of prodrugs: regulatory perspective. Pharmaceuticals. 2009;2:77-81.10.3390/ph2030077]Search in Google Scholar
[31. Wu KM, Farrelly J. Regulatory perspectives of type II prodrug development and time-dependent toxicity management: Nonclinical pharm/tox analysis and the role of comparative toxicology. Toxicology. 2007;236:1-6.10.1016/j.tox.2007.04.005]Search in Google Scholar
[32. Balendiran GK, Rath N, Kotheimer A. Biomolecular chemistry of isopropyl fibrates. J Pharm Sci. 2012;101(4):1555-1569.10.1002/jps.23040]Search in Google Scholar
[33. Lesniewska MA, Ostrowski T, Zeidler J, et al. Ester groups as carriers of antivirally active tricyclic analogue of acyclovir in prodrugs designing: synthesis, lipophilicity-comparative statistical study of the chromatographic and theoretical methods, validation of the HPLC method. Comb Chem High Throughput Screen. 2014;17(7):639-650.10.2174/1386207317666140526100532]Search in Google Scholar
[34. Chanteux H, Rosa M, Delatour C, et al. In vitro hydrolysis and transesterification of CDP323, an α4β1/α4β7 integrin antagonist ester prodrug. Drug Metab Dispos. 2014;42(1):153-161.10.1124/dmd.113.054049]Search in Google Scholar
[35. Swaan PW, Stehouwer MC, Tukker JJ. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat and lisinopril. Biochim Biophys Acta. 1995;1236(1):31-38.10.1016/0005-2736(95)00030-7]Search in Google Scholar
[36. Liu KS, Hsieh PW, Aljuffali IA, et al. Impact of ester promoieties on transdermal delivery of ketorolac. J Pharm Sci. 2014;103(3):974-986.10.1002/jps.2388824481782]Search in Google Scholar
[37. Karaman R. Computer-assisted design for atenolol prodrugs for the use in aqueous formulations. J Mol Model. 2012;18(4):1523-1540.10.1007/s00894-011-1180-721785934]Search in Google Scholar
[38. Wang H, Xie H, Wu J, et al. Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery platforms for enhanced antitumor efficacy. Angew Chem Int Ed. 2014;53(43):11532-11537.10.1002/anie.201406685422546825196427]Search in Google Scholar
[39. Lang BC, Yang J, Wang Y, et al. An improved design of water-soluble propofol prodrugs characterized by rapid onset of action. Anesth Analg. 2014;118(4):745-754.10.1213/ANE.000000000000012424651228]Search in Google Scholar
[40. Wozniak KM, Vornov JJ, Mistry BM. Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers. J Transl Med. 2015;13:170.10.1186/s12967-015-0526-9444831326021605]Search in Google Scholar
[41. Sharma SK, Bagshawe KD. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Springer 2010;393-405.10.1007/978-1-4419-0507-9_11]Search in Google Scholar
[42. Tietze L, Krewer B. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. Chem Biol Drug Des. 2009;74:205-211.10.1111/j.1747-0285.2009.00856.x19660031]Search in Google Scholar
[43. Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs II: the prodrug strategy. Drug Discovery Today. 2013;18(1-2):93-98.10.1016/j.drudis.2012.08.00622960308]Search in Google Scholar
[44. Tietze LF, Krewer B. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. Chem Biol Drug Des. 2009;74:205-211.10.1111/j.1747-0285.2009.00856.x]Search in Google Scholar
[45. Schmoll HJ, Twelves C, Sun W, et al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III coloncancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol. 2014;15(13):1481-1492.10.1016/S1470-2045(14)70486-3]Search in Google Scholar
[46. Loke J, Khan JN, Wilson JS, et al. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol. 2015;94(3):361-373.10.1007/s00277-014-2218-6431751925284166]Search in Google Scholar
[47. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021-3032.10.1200/JCO.2014.55.3628416249825092781]Search in Google Scholar
[48. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838-4841.10.1182/blood-2013-03-49048223591788]Search in Google Scholar
[49. Singh Y, Palombo M, Sinko PJ. Recent Trends in Targeted Anticancer Prodrug and Conjugate Design. Curr Med Chem. 2008;15(18):1802-1826.10.2174/092986708785132997280222618691040]Search in Google Scholar
[50. Aloysius H, Hu L. Targeted prodrug approaches for hormone refractory prostate cancer. Med Res Rev. 2015;35(3):554-585.10.1002/med.2133325529338]Search in Google Scholar
[51. Schellmann N, Deckert PM, Bachran D, et al. Targeted enzyme prodrug therapies. Mini Rev Med Chem. 2010;10:887-904.10.2174/13895571079200719620560876]Search in Google Scholar
[52. Osipovitch DC, Parker AS, Makokha CD, et al. Design and analysis of immune-evading enzymes for ADEPT therapy. Protein Eng Des Sel. 2012;25(10):613-623.10.1093/protein/gzs044344940122898588]Search in Google Scholar
[53. Zhou X, Wang H, Shi P, et al. Characterization of a fusion protein of RGD4C and the β-lactamase variant for antibody-directed enzyme prodrug therapy. Onco Targets Ther. 2014;7:535-541.10.2147/OTT.S59346398627424748803]Search in Google Scholar
[54. Zhang J, Kale V, Chen M. Gene-directed enzyme prodrug therapy. AAPS J. 2015;17(1):102-110.10.1208/s12248-014-9675-7428728625338741]Search in Google Scholar